Westlake Chemical Partners (WLKP) EPS Growth And 8.04% Yield Test Income Bull Narrative

Westlake Chemical Partners (WLKP) opened 2026 with Q1 revenue of US$305.7 million and basic EPS of US$0.40, alongside trailing 12 month revenue of about US$1.2 billion and EPS of US$1.64 that reflect 6.7% revenue growth and 10.3% EPS growth over the past year. Over that period, revenue has moved from US$1.09 billion to US$1.23 billion, while EPS has shifted from US$1.49 to US$1.64, giving investors a clearer read on how the current quarter fits into the last year of results. With net margin holding around the mid single digits and only slightly lower year over year, the latest numbers present a steady but finely balanced profitability picture.

See our full analysis for Westlake Chemical Partners.

With the headline figures on the table, the next step is to see how these earnings line up with the widely held narratives about Westlake Chemical Partners, and where the story investors tell themselves might need an update.

Curious how numbers become stories that shape markets? Explore Community Narratives

6.7% revenue growth trails US market

• Over the last 12 months, revenue grew 6.7% to about US$1.23b on a trailing basis, compared with 11.3% growth for the broader US market.
• For a bullish view that favors steady, contracted businesses, what stands out is that this 6.7% revenue growth and 10.3% EPS growth come alongside a fairly stable net margin of 4.7% versus 4.8% last year. This supports the idea of a more infrastructure-style profile, while also showing growth running slower than the wider market.

Net margin holds near 4.7%

• Net income over the last 12 months was US$57.9 million on US$1.23b of revenue, which lines up with a 4.7% net margin, only slightly different from the prior 4.8% level.
• Critics with a bearish tilt point to earnings declining 8.3% per year over five years. That history sits awkwardly alongside the recent 10.3% EPS growth and broadly steady margins, suggesting the recent improvement is visible in the numbers but has not yet changed the longer multiyear earnings trend.

High yield with stretched coverage

• The units offer an 8.04% dividend yield. Trailing EPS of US$1.64 and net income of US$57.9 million are described as not fully covering the payout and are paired with a high level of debt.
• For a cautious, bearish take, the key point is that this combination of an 8.04% yield, weaker dividend coverage and elevated leverage sits next to five-year earnings declines of 8.3% per year. The current income stream looks attractive on the surface yet clearly leans on a balance sheet that already carries significant debt.

Income focused investors who want to see how others weigh that trade off between an 8.04% yield, leverage, and recent growth can check the shared community views in more detail through the Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Westlake Chemical Partners's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With mixed signals on income, leverage and recent growth, the key question is how you weigh the trade off between risk and reward for your own portfolio. If you want a clearer picture before deciding what comes next, review the 2 key rewards and 3 important warning signs

See What Else Is Out There

Slower revenue growth than the broader US market, five year earnings declines and an 8.04% yield with stretched coverage and high debt all point to financial pressure.

If that mix of weaker long term earnings and leveraged income makes you uneasy, you may wish to compare it with companies screened for stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com